Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon Inks Deal To Market Fentora In China

This article was originally published in The Pink Sheet Daily

Executive Summary

Beijing Med-Pharm will carry out the clinical development and registration process for select Cephalon products, starting with the Actiq follow on.

You may also be interested in...



Beijing Med-Pharm Inks Deal With KV Pharmaceutical To Bring Clindesse To China

Beijing Med-Pharm will extend its women's health franchise in China with the addition of KV Pharmaceutical Company's Clindesse (clindamycin) for bacterial vaginosis. The company gained exclusive marketing and distribution rights to the product in China in a deal announced July 10

Beijing Med-Pharm Inks Deal With KV Pharmaceutical To Bring Clindesse To China

Marketing and distribution firm will be responsible for completing late-stage clinical development and registration of clindamycin.

Beijing Med-Pharm Inks Deal With KV Pharmaceutical To Bring Clindesse To China

Marketing and distribution firm will be responsible for completing late-stage clinical development and registration of clindamycin.

Related Content

Topics

UsernamePublicRestriction

Register

PS063515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel